Sevda İSMAİLOĞULLARI, Recep BAYDEMİR, Meral MİRZA, Murat GÜLTEKİN, Fatih TANRIVERDİ

Evaluation of serum cortisol and dehydroepiandrosterone sulphate levels in parkinson patients with and without postural instability

Amaç: Parkinson hastalığı (PH) ikinci sıklıkta görülen nörodejeneratif bir hastalıktır. Hastalık süresince otonom disfonksiyon ile beraber pek çok nöroendokrin mekanizmada bozukluk meydana gelmektedir. Bu çalışmadaki amaç; postural instabilitesi (Pİ) olan orta ve ileri evredeki idiopatik PH'li hastalarda serum kortizol ve dehidroepiandrosteron sülfat (DHEAS) değerlerini değerlendirmektir. Yöntemler: Çalışmaya her biri 30 bireyden oluşan Pİ olan hastalar, erken evre Pİ olmayan hastalar ve kontrol grubu alındı. Hastaların sabah açlık serum kortizol ve DHEAS değerleri ölçüldü.Bulgular: Serum kortizol düzeyi Pİ olan ileri evre hasta grubunda DHEAS ise Pİ olmayan erken evre hasta grubunda anlamlı olarak yüksek bulundu. Sonuç: Bu durum; PH'de görülen ilerleyici nörodejenerasyona sekonder olarak ortaya çıkan nöroendokrin cevabın yansıması olarak değerlendirildi. Elde edilen veriler, PH'de orta ve ileri evrede hastalık patofizyolojisinin daha iyi anlaşılmasına ve hastalar için gelecekte ilave tedavi seçeneklerinin oluşturulması yönünden katkı sağlamaktadır

Postural instabilitesi olan ve olmayan parkinsonlu hastalarda serum kortizol ve dehidroepiandrosteron sülfat düzeylerinin değerlendirilmesi

Objective: Parkinson's disease (PD) is the second most common neurodegenerative disease. During PD many disorders occur in the neuroendocrine mechanism along with autonomic dysfunction. The aim of this study was to evaluate the values of cortisol and dehydroepiandrosterone sulphate (DHEAS) in idiopathic PD patients with postural instability (PI) in the medium and advanced stages of the disease. Methods: Three groups were included in this study; patients with PI, patients without PI and control subjects. Each of the groups consisted of 30 patients. The fasting serum cortisol and DHEAS values of patients were obtained. Results: Serum cortisol levels were significantly higher in patients with PI in the advanced stage of PD, whereas DHEAS levels were significantly higher in patients without PI in the early stage. Conclusion: This situation was evaluated as the reflection of neuroendocrine response that occurred secondary to the progressive advancing neurodegeneration seen in PD patients. The data obtained may contribute to a better understanding of the pathophysiology of PD that in intermediate and advanced stages. In addition, our findings may help in establishing new treatment options for PD patients in the future. J Clin Exp Invest 2014; 5 (3): 376-380

PDF

___

Skogar Ö, Fall PA, Hallgren G. et al. Diurnal salivary cortisol concentrations in Parkinson's disease: in- creased total secretion and morning cortisol concen- trations. Int J General Med 2011;4:561-569.
Kim SD, Allen NE, Canning CG, Fung VSC. Postural instability in patients with Parkinson's Disease. CNS Drugs 2013;27:97-112.
Eser D, Baghai TC, Schule C, et al. Neuroactive ste- roids as endogenous modulators of anxiety. Curr Pharm Des 2008;14:3525-3533.
Charlett A, Dobbs JR, Purkiss AG. et al. Cortisol is higher parkinsonism and associated with gait deficit. Acta Neurol Scand 1998;97:77-85.
Leblhuber F, Peichl M. Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. Journal of Neurological sciences 1995:132:76-79.
Genedani S, Rasio B, Cortelli P, et al. Studies on Ho- mocysteine and Dehydroepiandrosterone Sulphate Plasma Levels in Alzheimer's Disease Patients and in Parkinson's Disease Patients. Neurotoxicity Research 2004;4:327-332.
Rabey JM, Scharf M, Oberman Z, et al. Cortisol, ACTH, and beta-endorphin after dexamethasone ad- ministration in Parkinson's dementia. Biol Psychiatry 1990;6:581-591.
Djamshidian A, O'Sullivan SS, Papadopoulos A, et al. Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J Neurol Neurosurg Psy- chiatry 2011;82:1107-1111.
Wolkowitz OM. Prospective controlled studies of the behavioral and biological effects of exogenous corti- costeroids. Psychoneuroendocrinology 1994;19:233- 255.
Pelletier G Steroidogenic enzymes in the brain: mor- phological aspects. Prog Brain Res 2010;181:193- 207.
Luchetti S, Huiting A, Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis. Neurosci- ence 2011;191:6-21.
Bélanger N, L Grégoire, PJ Bédard and T Di Paolo, Estradiol and dehydroepiandrosterone potentiate le- vodopa-induced locomotor activity in 1-methyl-4-phe- nyl-,2,3,6 tetrahydro pyridine monkeys. Endocrine 2003;21:97-101.
Wolf OT, Koster B, Kirschbaum C, et al. A single ad- ministration of dehydroepiandrosterone does not en- hance memory performance in young healthy adults, but immediately reduces cortisol levels. Biol Psychia- try 1997;42:845-848.
Wolkowitz OM, Reus VI. Treatment of depres- sion with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711.
Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994;37:1305- 1310.